Browsed by
Tag: Arena

Swimwear Market to reach USD 1.56 bn by 2024, Arena Spa and Chantelle Group emerge as Key Contributors to growth

Swimwear Market to reach USD 1.56 bn by 2024, Arena Spa and Chantelle Group emerge as Key Contributors to growth

Technavio has been monitoring the swimwear market and it is poised to grow by $ 1.56 bn during 2020-2024, progressing at a CAGR of almost 2% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201013005198/en/

Technavio has announced its latest market research report titled Global Swimwear Market 2020-2024 (Graphic: Business Wire)

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavio’s in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report on COVID-19

Frequently Asked Questions:

  • What are the major trends in the market?
    The rise in the number of swimming pools is a major trend driving the growth of the. market

  • At what rate is the market projected to grow?
    The year-over-year growth for 2020 is estimated at -15.37% and the incremental growth of the market is anticipated to be $ 1.56 bn.

  • Who are the top players in the market?
    Arena Spa, Chantelle Group, Gildan Activewear Inc., LVMH Moet Hennessy – Louis Vuitton, Perry Ellis International Inc., PVH Corp., Seafolly Holdings Pty. Ltd., SUNSETS Inc., Tapestry Inc., and Wacoal Holdings Corp., are some of the major market participants.

  • What is the key market driver?
    The increasing demand for long-sleeve swimsuits is one of the major factors driving the market.

  • How big is the APAC market?
    The APAC region will contribute 39% of the market share.

     

The market is fragmented, and the degree of

Read the rest
Arena Pharmaceuticals’ Presence at United European Gastroenterology Week Strengthens Ongoing Commitment to the Gastrointestinal Disease Community

Arena Pharmaceuticals’ Presence at United European Gastroenterology Week Strengthens Ongoing Commitment to the Gastrointestinal Disease Community

SAN DIEGO, Oct. 9, 2020 /PRNewswire/ — Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new data from the Phase 2 OASIS trial and its open-label extension for its investigative drug candidate etrasimod, a next-generation, once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator, in patients with moderately to severely active ulcerative colitis (UC) at the 26th Annual United European Gastroenterology (UEG) Week. Arena will also present preclinical data for olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2), in development for the treatment of visceral pain in gastrointestinal (GI) diseases. UEG Week is taking place virtually October 11-13, 2020.

Arena Sponsored Symposium Details: 
Title: Opening the Door to Emerging Investigational Treatments in Ulcerative Colitis: What Awaits Us?
Intended Audience: This symposium is designed for non-US healthcare professionals and is not affiliated with UEGW
Speakers: William Sandborn, MD (Chair), Professor Silvio Danese, Remo Panaccione, MD, FRCPC
Day/Time: Monday, October 12 at 17:30 CET

Presentation Details:
Title: Early and Durable Symptom Control in Patients with Moderately to Severely Active Ulcerative Colitis Treated with Etrasimod in the Randomised, Double Blind, Placebo Controlled, Phase 2 OASIS Trial and Open Label Extension
Day/Time: Tuesday, October 13, 2020, from 15:00-16:00 CET
ePoster: P0481

Title: Expression of Cannabinoid Receptors and the Effect of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, on Visceral Hypersensitivity in Rodent Models of Irritable Bowel Syndrome and Inflammatory Bowel Disease 
Day/Time: Sunday, October 11, 2020, 18:00-19:00 CET    
Oral presentation: OP058    

Title: The Incremental Increasing Rate of Thromboembolic Events in Patients with Inflammatory Bowel Disease Compared to Patients Without Autoimmune Disorder   
Event: Virtual poster exhibition
ePoster: P0377                    

About Etrasimod
Etrasimod (APD334) is a once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator, discovered by Arena, designed

Read the rest